Should Men and Women with HFpEF be Treated Differently?

November 14, 2020
Patrick Campbell

Conference | <b>AHA 2020</b>

Professor John McMurray offers insight into a discussion he led at AHA 2020 exploring the notion that treatment of men and women with heart failure with preserved ejection fraction should be approached differently.

Alongside multiple sessions aimed at addressing racial disparities in care at the American Heart Association (AHA) Scientific Sessions 2020 were sessions and studies with the goal of addressing gender disparities in cardiovascular care. Among these was a session on opening day of the meeting titled, “5 Questions about Heart Disease in Women”.

Included in speakers for the session was John McMurray, MD, professor of Cardiology at the University of Glasgow, who led a discussion around the question of whether women and men with heart failure with preserved ejection fraction (HFpEF) should receive different treatments. To learn more about this session and the idea that the pathology of HFpEF in men versus women could warrant different treatment approaches, Practical Cardiology asked McMurray to further explain the concept in an AHA 2020 House Call.